MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis

Xiaoman Wo^{a, #},
Dong Han^{a, #},
Haiming Sun^a,
Yang Liu^a,
Xiangning Meng^a,
Jing Bai^a,
Feng Chen^a,
Yang Yu^a,
Yan Jin^{a, b},
Songbin Fu^{a
, ,}

a.
Laboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China
b.
Key Laboratory of Medical Genetics (Harbin Medical University), Heilongjiang Higher Education Institutions, Harbin 150081, China

More Information

Corresponding author: E-mail address: fusongbin@yahoo.com (Songbin Fu)

These authors contributed equally to this work.

摘要

- /
- /
Abstract: The potentially functional polymorphism, SNP309, in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies showed inconclusive results. To obtain a more precise estimate of the association between MDM2 SNP309 and risk of cancer, we performed a meta-analysis of 70 individual studies in 59 publications that included 26,160 cases with different types of tumors and 33,046 controls. Summary odds ratios (OR) and corresponding 95% confidence intervals (CIs) were estimated using fixed- and random-effects models when appropriate. Overall, the variant genotypes were associated with a significantly increased cancer risk for all cancer types in different genetic models (GG vs. TT: OR, 1.123; 95% CI, 1.056–1.193; GG/GT vs. TT: OR, 1.028; 95% CI, 1.006–1.050). In the stratified analyses, the increased risk remained for the studies of most types of cancers, Asian populations, and hospital- /population-based studies in different genetic models, whereas significantly decreased risk was found in prostate cancer (GG vs. TT: OR, 0.606; 95% CI, 0.407–0.903; GG/GT vs. TT: OR, 0.748; 95% CI, 0.579–0.968). In conclusion, the data of meta-analysis suggests that MDM2 SNP309 is a potential biomarker for cancer risk.
- Polymorphism /
- Cancer risk /
- Meta-analysis
These authors contributed equally to this work.
注释:

HTML全文

参考文献(91)

[1]	Akisik, E., Yazici, H., Dalay, N. Mol. Biol. Rep., 1 (2010),pp. 343-348
[2]	Akkiz, H., Sumbul, A.T., Bayram, S. et al. Cancer Epidemiol., 34 (2010),pp. 448-452
[3]	Alazzouzi, H., Suriano, G., Guerra, A. et al. J. Med. Genet., 44 (2007),pp. 75-80
[4]	Alhopuro, P., Ylisaukko-Oja, S.K., Koskinen, W.J. et al. J. Med. Genet., 42 (2005),pp. 694-698
[5]	Arva, N.C., Gopen, T.R., Talbott, K.E. et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells J. Biol. Chem., 280 (2005),pp. 26776-26787
[6]	Ashton, K.A., Proietto, A., Otton, G. et al. Gynecol. Oncol., 113 (2009),pp. 109-114
[7]	Asomaning, K., Reid, A.E., Zhou, W. et al. Clin. Cancer Res., 14 (2008),pp. 4010-4015
[8]	Boersma, B.J., Howe, T.M., Goodman, J.E. et al. J. Natl. Cancer Inst., 98 (2006),pp. 911-919
[9]	Bond, G.L., Hu, W., Levine, A. Cancer Res., 65 (2005),pp. 5481-5484
[10]	Bond, G.L., Hu, W., Bond, E.E. et al. Cell, 119 (2004),pp. 591-602
[11]	Campbell, I.G., Eccles, D.M., Choong, D.Y. Cancer Lett., 240 (2006),pp. 195-197
[12]	Capasso, M., Ayala, F., Avvisati, R.A. et al. J. Hum. Genet., 55 (2010),pp. 518-524
[13]	Chen, X., Sturgis, E.M., Lei, D. et al. Cancer Res., 70 (2010),pp. 7199-7208
[14]	Chen, Y.L., Chang, Y.S., Chang, J.G. et al. Anal. Bioanal. Chem., 394 (2009),pp. 1291-1297
[15]	Cho, Y.G., Choi, B.J., Song, J.H. et al. Neoplasma, 55 (2008),pp. 256-260
[16]	Chua, H.W., Ng, D., Choo, S. et al. BMC Cancer, 10 (2010),p. 88
[17]	Cox, D.G., Deer, D., Guo, Q. et al. Cancer Causes Control, 18 (2007),pp. 621-625
[18]	DerSimonian, R., Laird, N. Meta-analysis in clinical trials Control. Clin. Trials, 7 (1986),pp. 177-188
[19]	Dharel, N., Kato, N., Muroyama, R. et al. Clin. Cancer Res., 12 (2006),pp. 4867-4871
[20]	Egger, M., Davey Smith, G., Schneider, M. et al. Bias in meta-analysis detected by a simple, graphical test BMJ, 315 (1997),pp. 629-634
[21]	El Hallani, S., Marie, Y., Idbaih, A. et al. J. Neurooncol., 85 (2007),pp. 241-244
[22]	Ellis, N.A., Huo, D., Yildiz, O. et al. Blood, 112 (2008),pp. 741-749
[23]	Ezzikouri, S., El Feydi, A.E., Afifi, R. et al. Cancer Detect. Prev., 32 (2009),pp. 380-385
[24]	Freedman, D.A., Wu, L., Levine, A.J. Functions of the MDM2 oncoprotein Cell. Mol. Life Sci., 55 (1999),pp. 96-107
[25]	Gangwar, R., Mittal, R.D. Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population DNA Cell Biol., 29 (2010),pp. 349-356
[26]	Grochola, L.F., Muller, T.H., Bond, G.L. et al. Pancreas, 39 (2010),pp. 76-80
[27]	Hamid, S., Yang, Y.H., Peng, K.N. et al. Oral Oncol., 45 (2009),pp. 496-500
[28]	Haupt, Y., Maya, R., Kazaz, A. et al. Mdm2 promotes the rapid degradation of p53 Nature, 387 (1997),pp. 296-299
[29]	Hirata, H., Hinoda, Y., Kikuno, N. et al. Clin. Cancer Res., 13 (2007),pp. 4123-4129
[30]	Hirata, H., Hinoda, Y., Kikuno, N. et al. J. Urol., 181 (2009),pp. 1907-1912
[31]	Hirschhorn, J.N., Lohmueller, K., Byrne, E. et al. A comprehensive review of genetic association studies Genet. Med., 4 (2002),pp. 45-61
[32]	Hong, Y., Miao, X., Zhang, X. et al. Cancer Res., 65 (2005),pp. 9582-9587
[33]	Horikawa, Y., Nadaoka, J., Saito, M. et al. Oncol. Rep., 20 (2008),pp. 49-55
[34]	Hu, Z., Jin, G., Wang, L. et al. Cancer Epidemiol. Biomarkers Prev., 16 (2007),pp. 2717-2723
[35]	Hu, Z., Ma, H., Lu, D. et al. Int. J. Cancer, 118 (2006),pp. 1275-1278
[36]	Jun, H.J., Park, S.H., Lee, W.K. et al. Mol. Carcinog, 46 (2007),pp. 100-105
[37]	Kang, S., Wang, D.J., Li, W.S. et al. Int. J. Gynecol. Cancer, 19 (2009),pp. 572-577
[38]	Khatri, R.G., Navaratne, K., Weil, R.J. J. Neurosurg., 109 (2008),pp. 842-848
[39]	Kibel, A.S., Jin, C.H., Klim, A. et al. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma Prostate, 68 (2008),pp. 1179-1186
[40]	Kinyamu, H.K., Archer, T.K. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression Mol. Cell. Biol., 23 (2003),pp. 5867-5881
[41]	Kubbutat, M.H., Jones, S.N., Vousden, K.H. Regulation of p53 stability by Mdm2 Nature, 387 (1997),pp. 299-303
[42]	Lang, A., Palmeback Wegman, P., Wingren, S. Rep, 22 (2009),pp. 575-579
[43]	Leu, J.D., Lin, I.F., Sun, Y.F. et al. World J. Gastroenterol., 15 (2009),pp. 5592-5597
[44]	Li, G., Zhai, X., Zhang, Z. et al. Carcinogenesis, 27 (2006),pp. 2028-2033
[45]	Lind, H., Zienolddiny, S., Ekstrom, P.O. et al. Int. J. Cancer, 119 (2006),pp. 718-721
[46]	Liu, G., Wheatley-Price, P., Zhou, W. et al. Int. J. Cancer, 122 (2008),pp. 915-918
[47]	Liu, J.N., Zhang, X.M., Guo, Y.L. et al. Chin. J. Oncol., 30 (2008),pp. 335-338
[48]	Ma, H., Hu, Z., Zhai, X. et al. Cancer Lett., 240 (2006),pp. 261-267
[49]	Mantel, N., Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease J. Natl. Cancer Inst., 22 (1959),pp. 719-748
[50]	Marcel, V., Palmero, E.I., Falagan-Lotsch, P. et al. J. Med. Genet., 46 (2009),pp. 766-772
[51]	Meissner Rde, V., Barbosa, R.N., Fernandes, J.V. et al. Cancer Detect. Prev., 31 (2007),pp. 371-374
[52]	Michael, D., Oren, M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol., 13 (2003),pp. 49-58
[53]	Millikan, R.C., Heard, K., Winkel, S. et al. Cancer Epidemiol. Biomarkers Prev., 15 (2006),pp. 175-177
[54]	Misra, C., Majumder, M., Bajaj, S. et al. Mol. Carcinog., 48 (2009),pp. 790-800
[55]	Mittelstrass, K., Sauter, W., Rosenberger, A. et al. BMC Cancer, 8 (2008),p. 113
[56]	Momand, J., Zambetti, G.P., Olson, D.C. et al. Cell, 69 (1992),pp. 1237-1245
[57]	Nakashima, M., Kondo, S., Shimizu, Y. et al. Acta Otolaryngol., 128 (2008),pp. 808-813
[58]	Nan, H., Qureshi, A.A., Hunter, D.J. et al. Cancer Causes Control, 20 (2009),pp. 171-179
[59]	Nunobiki, O., Ueda, M., Yamamoto, M. et al. Hum. Cell, 22 (2009),pp. 101-106
[60]	Ohmiya, N., Taguchi, A., Mabuchi, N. et al. J. Clin. Oncol., 24 (2006),pp. 4434-4440
[61]	Onat, O.E., Tez, M., Ozcelik, T. et al. Anticancer Res., 26 (2006),pp. 3473-3475
[62]	Park, S.H., Choi, J.E., Kim, E.J. et al. Lung Cancer, 54 (2006),pp. 19-24
[63]	Paulin, F.E., O’Neill, M., McGregor, G. et al. BMC Cancer, 8 (2008),p. 281
[64]	Perfumo, C., Parodi, S., Mazzocco, K. et al. Pediatr. Blood Cancer, 53 (2009),pp. 576-583
[65]	Petenkaya, A., Bozkurt, B., Akilli-Ozturk, O. et al. Anticancer Res., 26 (2006),pp. 4975-4977
[66]	Phillips, C.L., Gerbing, R., Alonzo, T. et al. Pediatr. Blood Cancer, 55 (2010),pp. 248-253
[67]	Pine, S.R., Mechanic, L.E., Bowman, E.D. et al. Cancer Epidemiol. Biomarkers Prev., 15 (2006),pp. 1559-1561
[68]	Schmidt, M.K., Reincke, S., Broeks, A. et al. Cancer Res., 67 (2007),pp. 9584-9590
[69]	Singh, V., Rastogi, N., Mathur, N. et al. Ann. Epidemiol., 18 (2008),pp. 48-57
[70]	Sotamaa, K., Liyanarachchi, S., Mecklin, J.P. et al. Clin. Cancer Res., 11 (2005),pp. 6840-6844
[71]	Stoehr, R., Hitzenbichler, F., Kneitz, B. et al. Br. J. Cancer, 99 (2008),pp. 78-82
[72]	Sun, Y.F., Leu, J.D., Chen, S.M. et al. BMC Cancer, 9 (2009),p. 13
[73]	Terry, K., McGrath, M., Lee, I.M. et al. Cancer Epidemiol. Biomarkers Prev., 17 (2008),pp. 983-986
[74]	Toffoli, G., Biason, P., Russo, A. et al. Clin. Cancer Res., 15 (2009),pp. 3550-3556
[75]	Tu, H.F., Chen, H.W., Kao, S.Y. et al. Radiother. Oncol., 87 (2008),pp. 243-252
[76]	Ueda, M., Yamamoto, M., Nunobiki, O. et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer Hum. Cell, 22 (2009),pp. 49-54
[77]	Walsh, C.S., Miller, C.W., Karlan, B.Y. et al. Gynecol. Oncol., 104 (2007),pp. 660-664
[78]	Wang, X., Yang, J., Ho, B. et al. Helicobacter, 14 (2009),pp. 114-119
[79]	Wasielewski, M., Nagel, J.H., Brekelmans, C. et al. Breast Cancer Res. Treat., 104 (2007),pp. 153-157
[80]	Wilkening, S., Bermejo, J.L., Hemminki, K. MDM2 SNP309 and cancer risk: a combined analysis Carcinogenesis, 28 (2007),pp. 2262-2267
[81]	Wilkening, S., Hemminki, K., Rudnai, P. et al. Br. J. Dermatol., 157 (2007),pp. 375-377
[82]	Wilkening, S., Bermejo, J.L., Burwinkel, B. et al. The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer Cancer Res., 66 (2006),pp. 646-648
[83]	Wu, Y.W., Prakash, K.M., Rong, T.Y. et al. Hum. Genet., 6 (2011),pp. 611-615
[84]	Xiao, M., Zhang, L., Zhu, X. et al. BMC Cancer, 10 (2010),p. 147
[85]	Xiong, X., Wang, M., Wang, L. et al. Leuk. Res., 33 (2009),pp. 1454-1458
[86]	Yang, M., Guo, Y., Zhang, X. et al. Carcinogenesis, 28 (2007),pp. 1996-2001
[87]	Yarden, R.I., Friedman, E., Metsuyanim, S. et al. Breast Cancer Res. Treat., 111 (2008),pp. 497-504
[88]	Zauberman, A., Flusberg, D., Haupt, Y. et al. Nucleic Acids Res., 23 (1995),pp. 2584-2592
[89]	Zhang, X., Miao, X., Guo, Y. et al. Hum. Mutat., 27 (2006),pp. 110-117
[90]	Zhang, Z., Zhang, R. p53-independent activities of MDM2 and their relevance to cancer therapy Curr. Cancer Drug Targets, 5 (2005),pp. 9-20
[91]	Zhou, G., Zhai, Y., Cui, Y. et al. Clin. Cancer Res., 13 (2007),pp. 2627-2633